Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000927016-03-002617
Filing Date
2003-05-14
Accepted
2003-05-13 18:47:50
Documents
9
Period of Report
2003-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6K d6k.htm 6-K 501723
3 PRESS RELEASE dex991.htm EX-99.1 9807
4 PRESS RELEASE dex992.htm EX-99.2 10293
5 PRESS RELEASE dex993.htm EX-99.3 6519
6 PRESS RELEASE dex994.htm EX-99.4 22670
7 PRESS RELEASE dex995.htm EX-99.5 6964
8 PRESS RELEASE dex996.htm EX-99.6 9749
9 PRESS RELEASE dex997.htm EX-99.7 8867
10 PRESS RELEASE dex998.htm EX-99.8 11710
  Complete submission text file 0000927016-03-002617.txt   590623
Mailing Address 28159 AVENUE STANFORD VALENCIA CA 91355
Business Address 5911 KJ VENLO SPOORSTRAAT P7 50 31-77-320-8400
QIAGEN NV (Filer) CIK: 0001015820 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 000-28564 | Film No.: 03696687
SIC: 2836 Biological Products, (No Diagnostic Substances)